Department of Radiotherapy, Second Hospital of Jilin University, Changchun, China.
National Health Commission (NHC) Key Laboratory of Radiobiology, School of Public Health, Jilin University, Changchun, China.
Front Immunol. 2023 Jul 3;14:1199273. doi: 10.3389/fimmu.2023.1199273. eCollection 2023.
Women worldwide are more likely to develop breast cancer (BC) than any other type of cancer. The treatment of BC depends on the subtype and stage of the cancer, such as surgery, radiotherapy, chemotherapy, and immunotherapy. Although significant progress has been made in recent years, advanced or metastatic BC presents a poor prognosis, due to drug resistance and recurrences. During embryonic development, myeloid-derived suppressor cells (MDSCs) develop that suppress the immune system. By inhibiting anti-immune effects and promoting non-immune mechanisms such as tumor cell stemness, epithelial-mesenchymal transformation (EMT) and angiogenesis, MDSCs effectively promote tumor growth and metastasis. In various BC models, peripheral tissues, and tumor microenvironments (TME), MDSCs have been found to amplification. Clinical progression or poor prognosis are strongly associated with increased MDSCs. In this review, we describe the activation, recruitment, and differentiation of MDSCs production in BC, the involvement of MDSCs in BC progression, and the clinical characteristics of MDSCs as a potential BC therapy target.
全球女性患乳腺癌（BC）的可能性高于其他任何类型的癌症。BC 的治疗取决于癌症的亚型和分期，例如手术、放疗、化疗和免疫疗法。尽管近年来取得了重大进展，但由于耐药性和复发，晚期或转移性 BC 的预后较差。在胚胎发育过程中，会产生髓样来源的抑制细胞（MDSCs），从而抑制免疫系统。MDSCs 通过抑制抗免疫作用并促进非免疫机制，如肿瘤细胞干性、上皮-间充质转化（EMT）和血管生成，有效促进肿瘤生长和转移。在各种 BC 模型、外周组织和肿瘤微环境（TME）中，都发现 MDSCs 扩增。临床进展或预后不良与 MDSCs 增加密切相关。在这篇综述中，我们描述了 MDSCs 在 BC 中的激活、募集和分化、MDSCs 在 BC 进展中的参与以及 MDSCs 作为潜在的 BC 治疗靶点的临床特征。
